I began my career at Ohio State University, establishing the country's first Department of Molecular Genetics along with the Ohio State Edison Incubator Program. As Director of the Experimental Therapeutics Program at the James Cancer Institute, OSU, I led significant cancer research initiatives. In 2004, I was recruited to the University of Central Florida to assist in creating a new medical school and directed the Cancer Consortium of Central Florida. My research (H-index >45) and extensive publications, focuses on carcinogenesis, particularly in epigenetic regulation and DNA repair pathways, identification of novel anti-cancer therapies and most recently biomarkers for Alzheimer's Disease.I am currently active on multiple boards and have founded several biotechnology startups, with TopoGEN, Inc. being the most successful, achieving global recognition. Since 2016, I've led TopoGEN, Inc. (CEO) which has received substantial state and federal support, including a relocation to Colorado and multiple SBIR grants. Our groundbreaking work includes developing a screening platform for epigenomic changes at the single-cell level, a significant advancement in drug discovery. This innovation has applications in Alzheimer's Disease research, where we are exploring serum-based biomarkers for early detection. TopoGEN, Inc. is actively collaborating with aligned startups to further this research.